{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000112","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.654668+00:00","generated_at":"2026-05-28T07:26:36.471436+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioCryst raises ORLADEYO WAC 5% to $44,484.33 per 28-day pack effective Jan 8","bullets":["ORLADEYO WAC raised from $42,366.03 to $44,484.33 per 28-day pack (150mg or 110mg).","Price increase of approximately 5% effective January 8, 2025.","The WAC increase applies to both the 150mg and 110mg capsule packs."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000112","json":"https://secwatch.observer/filing/0001171843-25-000112.json","markdown":"https://secwatch.observer/filing/0001171843-25-000112.md","text":"https://secwatch.observer/filing/0001171843-25-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325000112/0001171843-25-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325000112/f8k_010824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T07:26:36.471436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}